Liquid Biopsy Market Size Set to Surpass US$26.2 Billion by 2030

According to a news release by Precedence Research, the global liquid biopsy market size is expected to pass the $ 26.2 billion mark by 2030 and is anticipated to grow with a healthy growth rate of more than 14% over the forecast period 2021-2030.

The global liquid biopsy market was valued at USD 8.1 billion in 2021. The report contains 150+ pages with detailed analysis. The base year for the study has been considered 2021, the historic year 2017 to 2020, the forecast period considered is from 2021 to 2030.

The liquid biopsy market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit). The report offers exclusive insights to help companies make informed decisions to sustain growth through the assessment period.

Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1398

The global liquid biopsy market growth is driven by rapidly growing number of deaths linked to cancer and rising burden of various types of cancer such as neck and head cancer, colorectal cancer, lungs cancer, breast cancer, and bowel cancer. According to the International Agency for Research on Cancer, the around 19.3 million new cancer cases were observed in 2020 and is expected to grow by 47% to reach 28.4 million new cases by 2040. Therefore, the rising demand for the diagnosis of cancer is driving the demand for the liquid biopsy across the globe.

The liquid biopsy offer certain advantages over the traditional diagnosis techniques like low cost, accuracy, rapid results, and early detection, which makes the liquid biopsy a popular technique among the patients. Moreover, the technological advancements and rising number of developmental strategies being adopted by the market players is influencing the market growth. For instance, the Quest Diagnostics and the Biocept, Inc. collaborated to develop an advanced NGS for the lungs cancer patient in June 2021.

Scope of the Liquid Biopsy Market Report

Market Dynamics

Driver

Increasing awareness regarding the liquid biopsy

The increasing prevalence of cancer cases across the globe along with the proliferation in the diagnostic technologies has boosted the adoption of the liquid biopsy in the diagnosis of cancer. The increased awareness regarding the benefits of the liquid biopsy has fostered it demand. Liquid biopsy can efficiently detect even the rare mutations of the cancer. It provides low cost, fast and reliable diagnostic results, which is fueling the demand for the liquid biopsy across the globe.

Restraints

The lack of awareness regarding the benefits of liquid biopsy in the underdeveloped and developing markets is restricting the market growth. Moreover, low access to the healthcare facilities in the low and middle income countries due to the lack of adequate healthcare infrastructure is a major restraint for the liquid biopsy market.

Opportunities

The rising awareness regarding the non-invasive procedures among the population

The growing cases of cancer owing to the bad habits such as tobacco consumption and smoking is triggering the cancer cases to rise at a rapid rate across the globe. Moreover, the increased risk of metastatic conditions of the patient suffering from lungs cancer is boosting the adoption of the biomarker diagnosis. The increased investment in the research and development of the innovative testing techniques is fueling the demand for the non-invasive procedures among the global population.

Challenges

The unawareness regarding the actual cost of the diagnosis

Majority of the patient are unaware regarding the costs involved in the liquid biopsy. The cost is known to the stakeholders only after the reimbursement of the bill. This confusion associated with the costs and the reimbursements of the bill is a major challenge for the both the patients and the market players operating in the global liquid biopsy market.

Competitive Intelligence

The report provides an understanding of the market composition and explains the role of established players and regional contributors. It is essential for the market players to make calculative moves and focus on client acquisition and retention. The detailed company profiles will provide the necessary intelligence to the reader. In order to maintain their share, the market players are focusing on strategies such as cross-border expansion, product differentiation and so on.

Some of the prominent players in the global liquid biopsy market are listed as below:

• Bio-Rad Laboratories
• Biocept Inc.
• Guardant Health
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Laboratory Corporation of America Holdings
• MDxHealth SA
• QIAGEN N.V
• Thermo Fisher Scientific Inc.

Report Highlights

• Based on the technology, the PCR is expected to be the fastest-growing segment during the forecast period. This is due to the rising adoption of the PCR technique in the diagnosis of cancer owing to its low cost benefit, rapid results, and increased efficacy and accuracy. Moreover, the applications of the PCR is growing in detection of various fungal diseases, bacterial diseases, and other genomic applications, which is expected to drive the growth of the PCR segment.
• Based on the application, the cancer segment dominated the market owing to the increased prevalence of numerous types of cancer among the population and the increasing adoption of the liquid biopsy in the diagnosis. The growing burden of cancer and the increased need for its early detection has fueled the growth of this segment.
• Based on the circulating biomarker, the circulating tumor DNA is estimated to be the most opportunistic segment during the forecast period. This is attributable to the enhanced efficiency of the circulating tumor DNA to detect the cancer early and also detect its mutations. Moreover, this biomarker is extremely efficient for the detection of the breast cancer and the increasing prevalence of breast cancer is fostering the growth.According to the International Agency for Research on Cancer, breast cancer has surpassed the lungs cancer as the most diagnosed type of cancer across the globe in 2020.

Regional Snapshot

North America dominated the global liquid biopsy market in 2020. This is simply attributed to the increased healthcare expenditure and increased awareness regarding different types of cancer and advanced diagnostic technologies among the population. Moreover, the increased prevalence of cancer among the population in US has exponential contributions in the liquid biopsy market growth. According to the American Cancer Society, around 1.8 million new cancer cases were recorded in US and around 606,520 deaths were reported in 2020. Therefore, the rising cases of cancer among the US population has driven the growth of the liquid biopsy market in North America in the past few years.

Asia Pacific is expected to be the most opportunistic market in the foreseeable future. The rising government investments in the development of advanced hospitals and rising penetration of numerous diagnostic laboratories in the region is fueling the market growth. Moreover, the rising incidences of cancer and the presence of huge population is boosting the need for the development of technologically advanced healthcare units, which is spurring the demand for the liquid biopsy in Asia Pacific market.

Segments Covered in the Report

By Technology

• PCR
• NGS

By Application

• Cancer
  • Lungs Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others
• Non-Cancer

By Circulating Biomarker

• Circulating Tumor Cells
• Cell-Free DNA
• Circulating Tumor DNA
• Extracellular Vesicles
• Others

Regional Segmentation

– North America (U.S. and Canada)

 – Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)

 – Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)

 – Latin America (Brazil and Rest of Latin America)

– Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Why should you invest in this report?

If you are aiming to enter the global liquid biopsy market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for liquid biopsy are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Buy Full Research Report, Click Here@ https://www.precedenceresearch.com/checkout/1398

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Liquid Biopsy Market 

5.1. COVID-19 Landscape: Liquid Biopsy Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Liquid Biopsy Market, By Technology

8.1. Liquid Biopsy Market, by Technology Type, 2021-2030

8.1.1. PCR

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. NGS

8.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Liquid Biopsy Market, By Application

9.1. Liquid Biopsy Market, by Application, 2021-2030

9.1.1. Cancer (Lungs Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Others)

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Non-Cancer

9.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Liquid Biopsy Market, By Circulating Biomarker 

10.1. Liquid Biopsy Market, by Circulating Biomarker, 2021-2030

10.1.1. Circulating Tumor Cells

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Cell-Free DNA

10.1.2.1. Market Revenue and Forecast (2019-2030)

10.1.3. Circulating Tumor DNA

10.1.3.1. Market Revenue and Forecast (2019-2030)

10.1.4. Extracellular Vesicles

10.1.4.1. Market Revenue and Forecast (2019-2030)

10.1.5. Others

10.1.5.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Liquid Biopsy Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Technology (2019-2030)

11.1.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.1.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.1.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Technology (2019-2030)

11.2.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.2.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.2.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Technology (2019-2030)

11.2.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.6.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Technology (2019-2030)

11.2.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.7.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Technology (2019-2030)

11.3.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.3.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.3.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Technology (2019-2030)

11.3.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.6.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Technology (2019-2030)

11.3.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.7.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.4.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.4.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Technology (2019-2030)

11.4.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.6.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Technology (2019-2030)

11.4.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.7.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.5.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.4.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.5.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.5.3. Market Revenue and Forecast, by Circulating Biomarker (2019-2030)

Chapter 12. Company Profiles

12.1. Bio-Rad Laboratories

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Biocept Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Guardant Health

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Illumina, Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. F. Hoffmann-La Roche Ltd.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Johnson & Johnson

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Laboratory Corporation of America Holdings

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. MDxHealth SA

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. QIAGEN N.V

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Thermo Fisher Scientific Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1398

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com